한글목차

지방간 치료제의 동향과 전망

세계 지방간 치료제 시장의 미래는 병원 및 클리닉 시장에서의 기회로 인해 유망합니다. 세계 지방간 치료제 시장은 2024년부터 2030년까지 5.3%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 2030년까지 약 263억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 알코올 소비 증가와 당뇨병 유병률 증가입니다.

• Lucintel의 예측에 따르면, 의약품 카테고리에서 의약품은 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다.
• 최종 사용 분야에서는 병원이 높은 성장세를 보일 것으로 예상됩니다.
• 지역별로는 생활습관병 증가와 함께 약물 및 알코올 남용이 증가하고 있는 북미가 예측 기간 동안 가장 규모가 큰 지역으로 남을 것으로 보입니다.

지방간치료제 시장의 전략적 성장 기회

전체 지방간 치료제 시장의 주요 용도에는 여러 가지 전략적 성장 기회가 있습니다. 이러한 기회는 치료 옵션의 발전, 환자 인식 증가, 의료 서비스 접근성 증가에 의해 뒷받침되고 있습니다.

• 의약품의 발전: 신약 및 병용요법 개발에 대한 투자는 훌륭한 성장 기회가 될 수 있습니다. 새로운 제형과 표적 치료는 치료 효과를 개선하고 환자에게 더 나은 결과를 가져올 수 있습니다. 신약은 시장의 미충족 수요에 대한 새로운 치료 옵션을 제공하고 질병 관리와 환자 치료의 지속적인 개선을 지원할 수 있습니다.
• 진단 서비스 확대: 영상 및 임상 검사를 포함한 고급 진단에 대한 수요가 증가함에 따라 확장의 여지가 있습니다. 진단 도구가 강화되면 비만 및 알코올 과다 섭취와 관련된 다른 질병과 마찬가지로 지방간 질환의 조기 발견과 정확한 모니터링이 용이해집니다. 진단 서비스의 가용성이 높아지면 지방간 질환을 보다 효과적으로 식별하고 관리할 수 있어 더 나은 치료 계획과 환자 예후 개선에 도움이 될 것입니다.
• 라이프스타일/웰니스 프로그램: 식이요법, 운동요법 등 라이프스타일/웰니스 프로그램을 치료계획에 통합하는 것은 이 분야의 성장을 기대할 수 있는 부분입니다. 이러한 프로그램은 치료 개입 과정을 돕고 일반적인 건강 증진 활동에도 기여할 수 있습니다. 라이프 스타일 및 웰니스 프로그램은 환자 치료에 대한 보다 통합적인 접근 방식을 제공하여 순응도를 높이고 전반적인 치료 결과를 개선할 수 있습니다.
• 원격 의료 및 디지털 헬스: 원격 의료 및 디지털 헬스 툴의 도입은 원격 모니터링, 환자 교육 및 치료 관리의 기회를 창출합니다. 이러한 솔루션은 접근성과 환자 참여를 향상시킵니다. 원격 의료 및 디지털 건강 플랫폼은 지방간 질환을 관리하고, 환자의 치료 접근성을 개선하며, 지속적인 질병 관리를 지원하는 데 있어 확장성과 편리함을 제공합니다.
• 신흥 시장 : 의료 수요 증가와 인지도 상승을 특징으로 하는 신흥 시장에 진출하는 것은 큰 성장 기회가 될 것입니다. 이 시장들은 신약과 의료 솔루션에 대한 수요가 높은 시장입니다. 신흥 시장 진출은 세계 성장을 뒷받침하고 지방간 질환 관리에 대한 수요 증가에 대응하며 세계 건강 이니셔티브와 의료 접근성 향상에 부합합니다.

지방간 치료제 시장의 전략적 성장 수단으로는 의약품의 발전, 진단 서비스 확대, 라이프스타일 프로그램, 디지털 건강 제품, 신흥 시장 진출 등이 있습니다. 전 세계적으로 환자의 삶을 개선하고 더 나은 치료 서비스를 제공하기 위해 더 많은 치료 옵션이 개발되고 있기 때문에 시장의 미래는 이러한 기회 속에 있습니다.

지방간치료제 시장 활성화 요인 및 과제

지방간 치료제 시장은 비알코올성 지방간 질환(NAFLD)과 비알코올성 지방간염(NASH)에 대한 치료법 개발 및 제공에 초점을 맞추었습니다. 이러한 간 질환의 유병률이 전 세계적으로 증가함에 따라 시장은 크게 성장하고 있습니다.

지방간 치료제 시장을 이끄는 요인은 다음과 같습니다.

1.NAFLD와 NASH의 유병률 증가: 비만과 당뇨병과 같은 생활습관병이 전 세계적으로 증가함에 따라 효과적인 지방간 치료제에 대한 수요가 증가하고 있습니다.

2. 인지도 향상과 진단: 인지도 향상과 진단기술의 개선으로 지방간 질환의 발견율이 높아져 치료 수요가 증가하고 있습니다.

3. 의약품 개발의 발전: 의약품의 지속적인 연구개발로 지방간 치료제의 효과적인 신약이 등장하여 시장 개척을 촉진하고 있습니다.

4. 의료비 지출 증가: 특히 신흥국의 의료비 지출 증가는 만성질환 관리에 더 많은 자원을 할당하여 지방간 치료제 시장의 성장을 뒷받침하고 있습니다.

5. 정부의 이니셔티브와 지원: 비만과 대사 장애를 해결하기 위한 정부 프로그램은 관련 건강 문제에 초점을 맞추어 간접적으로 지방간 치료제 수요를 촉진하고 있습니다.

지방간 치료제 시장의 과제는 다음과 같습니다.

1. 높은 치료비: 특히 중저소득 국가에서는 새로 개발된 약품 및 치료법의 높은 비용이 치료의 장벽이 되어 시장 성장을 제한할 수 있습니다.

2. 현재 치료법의 부작용과 제한적인 효과: 기존 치료법은 대부분 부작용이 크거나 효과가 제한적이어서 환자와 의료진 모두 어려움을 겪고 있습니다.

3.3.3.NASH에 대한 승인된 치료제의 부족: NASH 치료에 특화된 FDA 승인 치료제의 부족은 시장에 격차를 가져와 이 질환의 관리를 방해하고 있습니다.

4. 질병 진행의 복잡성: 지방간 질환의 진행은 다인자적이기 때문에 만능 치료법 개발이 어려워 약물 개발의 난제입니다.

5. 규제 장애물: 의약품 승인에 대한 엄격한 규제 요건은 새로운 치료법 시장 도입을 지연시키고 성장 전망에 영향을 미칠 수 있습니다.

지방간 치료제 시장은 현대인의 생활습관 관련 간질환 유병률 증가와 의료에 대한 인식이 높아짐에 따라 성장이 예상되고 있습니다. 그러나 높은 치료 비용, 부작용, 규제적 장애물 등의 문제는 시장의 잠재력을 극대화하기 위해 해결해야 할 과제입니다. 효과적인 지방간 치료제에 대한 수요 증가에 대응하고 전 세계 환자들의 치료 결과를 개선하기 위해서는 혁신과 타겟팅 전략을 통해 이러한 장애물을 극복하는 것이 매우 중요합니다.

목차

제1장 주요 요약

제2장 세계의 지방간 치료제 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018년-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 지방간 치료제 시장 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 지방간 치료제 시장 : 약제별
  • Thiazolidinedione
  • Vitamin E
  • Metformin Statins
  • Polyunsaturated Fatty Acids
  • Angiotensin Receptor Blockers
  • Pentoxifylline
• 세계의 지방간 치료제 시장 : 최종 용도별
  • 병원
  • 클리닉

제4장 지역별 시장 동향과 예측 분석(2018년-2030년)

• 세계의 지방간 치료제 시장 : 지역별
• 북미의 지방간 치료제 시장
• 유럽의 지방간 치료제 시장
• 아시아태평양의 지방간 치료제 시장
• 기타 지역의 지방간 치료제 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 지방간 치료제 시장 성장 기회 : 약제별
  • 세계의 지방간 치료제 시장 성장 기회 : 최종 용도별
  • 세계의 지방간 치료제 시장 성장 기회 : 지역별
• 세계 지방간 치료제 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 지방간 치료제 시장 생산능력 확대
  • 세계 지방간 치료제 시장의 인수합병(M&A) 및 합작투자
  • 인증 및 라이선싱

제7장 주요 기업 개요

• Cardax
• Daewoong
• Hoffmann-La Roche
• Glenmark
• GW Pharmaceuticals

영문목차

Fatty Liver Treatment Trends and Forecast

The future of the global fatty liver treatment market looks promising with opportunities in the hospital and clinic markets. The global fatty liver treatment market is expected to reach an estimated $26.3 billion by 2030 with a CAGR of 5.3% from 2024 to 2030. The major drivers for this market are the growing alcohol consumption and the increasing prevalence of diabetes.

• Lucintel forecasts that, within the drug category, fatty liver treatment is expected to witness the highest growth over the forecast period.
• Within the end-use category, the hospital is expected to witness a higher growth.
• In terms of regions, North America will remain the largest region over the forecast period due to increasing drug and alcohol abuse along with growing incidence of lifestyle diseases.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Fatty Liver Treatment Market

The fatty liver treatment market is experiencing various emerging trends driven by advancements in medical research, technology, and patient care strategies. These developments are redefining how fatty liver diseases are treated globally.

• Personalized Medicine: Personalized medicine is becoming a dominant trend, where treatments are designed based on individual genetic profiles as well as lifestyle factors. This aims at maximizing therapeutic efficacy while minimizing side effects, making it a more effective method for managing fatty liver disease. Personalized treatments based on patient-specific data offer precise solutions that enhance outcomes and adherence. Genetic research, coupled with data analytics advancements, necessitates such plans, leading to improved treatment interventions.
• Integration of Digital Health Tools: The increasing use of digital health tools, such as mobile applications and wearable devices, allows for tracking patient progress and supporting behavior change management. These tools provide real-time updates about an individual's condition from a healthcare professional's perspective. Digital tools improve patient involvement and adherence to treatment plans while enabling better management of chronic conditions through continuous monitoring and data collection, ultimately improving overall treatment outcomes.
• Advances in Pharmacotherapy: Recent developments in pharmacotherapy include new drug classes and combination therapies targeting liver fat and inflammation. Innovations in drug delivery systems are also enhancing treatment options. New pharmacological treatments provide more effective solutions for managing fatty liver disease, offering additional choices for patients who do not respond well to existing therapies, leading to improved treatment outcomes.
• Focus on Lifestyle Interventions: There is a growing emphasis on incorporating lifestyle interventions, such as diet and exercise, into treatment plans. These interventions are critical for managing and even reversing fatty liver disease. Lifestyle changes play a crucial role in improving liver health and overall well-being. Integrating these interventions with medical treatments enhances patient outcomes and supports long-term disease management.
• Increased Research and Development: Investment in research and development is on the rise, with a focus on discovering new treatments and understanding the underlying mechanisms of fatty liver disease. Increased R&D efforts lead to the development of innovative therapies as well as a better understanding of the condition. This progress contributes to more effective treatments and better patient care.

The emerging trends in the fatty liver treatment market are leading to significant changes in how this condition is managed. Personalized medicine, digital health tools, advances in pharmacotherapy, lifestyle interventions, and increased R&D all contribute to changing treatment approaches, making them more effective and leading to better patient outcomes. These trends highlight enhanced business opportunities for developing individualized treatment methods that can be used holistically to manage fatty liver diseases.

Recent Developments in the Fatty Liver Treatment Market

Recent developments in the fatty liver treatment market reflect ongoing advancements in treatment options, diagnostics, and patient care strategies. These developments signal the future direction for managing fatty liver diseases.

• Approval of New Medications: The introduction of new medications, such as those targeting specific metabolic pathways and liver inflammation, has expanded treatment options. These drugs offer improved efficacy and reduced side effects compared to previous treatments, helping manage fatty liver disease more effectively. They provide additional options for patients who may not have responded to existing treatments, leading to improved overall outcomes.
• Advancements in Diagnostic Technologies: Innovations in imaging and diagnostic technologies, such as enhanced MRI and ultrasound techniques, have improved the accuracy of fatty liver disease assessments. Improved diagnostic tools enable earlier detection and more precise monitoring of disease progression. This advancement supports better treatment planning and management.
• Integration of Lifestyle Management Programs: There is a growing focus on integrating lifestyle management programs, including dietary changes and physical activity, into treatment plans for fatty liver disease. Incorporating lifestyle management enhances the effectiveness of medical treatments and promotes long-term disease reversal. This holistic approach supports overall health and well-being.
• Increased Funding for Research: Increased funding from both government and private sources is supporting research into new treatments and a better understanding of the pathophysiology of fatty liver disease. Enhanced research efforts contribute to the development of innovative therapies and improved disease management strategies. This investment drives progress and better patient outcomes.
• Expansion of Clinical Trials: The number of clinical trials currently being conducted to explore new forms or combinations of treatments for fatty liver disease is increasing. Clinical trials provide crucial information about the effectiveness and safety of new treatments, helping to find solutions that improve patient outcomes.

The fatty liver treatment market is growing due to developments in treatment options, diagnostics, and patient care strategies. The approval of new drugs, the development of diagnostic technologies, integration with lifestyle management, increased funding for research, and expanding clinical trials have shaped the future of fatty liver disease management. There is substantial improvement in treatment efficacy, which has led to better results for patients and illustrates ongoing progress in this field.

Strategic Growth Opportunities for Fatty Liver Treatment Market

Key applications across the fatty liver treatment market offer multiple strategic growth opportunities. These opportunities are underpinned by advances in treatment options, rising patient awareness, and increasing access to healthcare services.

• Pharmaceutical Advancements: Investments in developing novel pharmaceuticals or combination therapies present an excellent growth opportunity. New drug formulations and targeted therapies can result in improved therapeutic effects and more favorable outcomes for patients. Novel pharmaceuticals can provide additional treatment options to address unmet needs within the market, supporting ongoing improvements in disease management and patient care.
• Expansion of Diagnostic Services: Increasing demand for advanced diagnostics, including imaging and lab tests, provides room for expansion. Enhanced diagnostic tools facilitate early identification and accurate monitoring of fatty liver disease, as well as other conditions related to obesity or excessive alcohol use. Increased availability of diagnostic services enables more effective identification and management of fatty liver disease, supporting better treatment planning and improved patient outcomes.
• Lifestyle & Wellness Programs: Integrating lifestyle/wellness programs, such as dietary and exercise interventions, into treatment plans offers potential growth in this area. These programs aid the therapeutic intervention process and contribute to general health promotion activities. Lifestyle and wellness programs offer a more holistic approach to patient care, improving adherence rates and leading to better overall outcomes.
• Telemedicine and Digital Health: The adoption of telemedicine and digital health tools creates opportunities for remote monitoring, patient education, and treatment management. These solutions improve accessibility and patient engagement. Telemedicine and digital health platforms are scalable and convenient for managing fatty liver disease, improving patient access to care, and supporting ongoing disease management.
• Emerging Markets: Entering emerging markets, characterized by growing healthcare demands and increased awareness, presents a significant growth opportunity. These markets are ripe for new drugs and healthcare solutions. Expanding into emerging markets supports global growth and addresses the increasing demand for fatty liver disease management, aligning with global health initiatives and access to care.

Strategic growth avenues in the fatty liver treatment market include advancements in pharmaceuticals, expansion of diagnostic services, lifestyle programs, digital health products, and entry into emerging markets. The future of the market lies within these opportunities, as more treatment options are being developed to enhance patients' lives and provide better care services worldwide.

Fatty Liver Treatment Market Driver and Challenges

The fatty liver treatment market focuses on the development and provision of therapies for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), conditions characterized by the excessive accumulation of fat in the liver. As the prevalence of these liver conditions rises globally, the market is experiencing significant growth.

The factors driving the fatty liver treatment market include:

1. Rising Prevalence of NAFLD and NASH: The global increase in lifestyle-related conditions like obesity and diabetes is driving the demand for effective fatty liver treatments.

2. Growing Awareness and Diagnosis: Increased awareness and improved diagnostic techniques are leading to higher detection rates of fatty liver conditions, boosting demand for treatments.

3. Advancements in Drug Development: Ongoing research and development in pharmaceuticals are resulting in the introduction of new, more effective drugs for fatty liver treatment, driving market growth.

4. Increasing Healthcare Expenditure: Rising healthcare spending, particularly in emerging economies, is supporting the growth of the fatty liver treatment market as more resources are allocated to chronic disease management.

5. Government Initiatives and Support: Government programs aimed at addressing obesity and metabolic disorders are indirectly driving the demand for fatty liver treatments by focusing on related health issues.

Challenges in the fatty liver treatment market include:

1. High Cost of Treatment: The high cost of newly developed drugs and therapies can be a barrier to treatment, especially in low- and middle-income countries, limiting market growth.

2. Side Effects and Limited Efficacy of Current Therapies: Many existing treatments have significant side effects or limited efficacy, creating challenges for both patients and healthcare providers.

3. Lack of Approved Therapies for NASH: The lack of FDA-approved drugs specifically for NASH treatment creates a gap in the market, hindering the management of this condition.

4. Complexity of Disease Progression: The multifactorial nature of fatty liver disease progression makes it difficult to develop one-size-fits-all treatments, posing challenges for drug development.

5. Regulatory Hurdles: Stringent regulatory requirements for drug approval can delay the introduction of new therapies to the market, affecting growth prospects.

The fatty liver treatment market is poised for growth due to the rising prevalence of liver conditions linked to modern lifestyles and increased healthcare awareness. However, challenges such as high treatment costs, side effects, and regulatory hurdles need to be addressed to unlock the market's full potential. Overcoming these obstacles through innovation and targeted strategies will be crucial in meeting the growing demand for effective fatty liver treatments and improving patient outcomes globally.

List of Fatty Liver Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies fatty liver treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the fatty liver treatment companies profiled in this report include-

• Cardax
• Daewoong
• Hoffmann-La Roche
• Glenmark
• GW Pharmaceuticals

Fatty Liver Treatment by Segment

The study includes a forecast for the global fatty liver treatment by drug, end use, and region.

Fatty Liver Treatment Market by Drug [Analysis by Value from 2018 to 2030]:

• Thiazolidinedione
• Vitamin E
• Metformin Statins
• Polyunsaturated Fatty Acids
• Angiotensin Receptor Blockers
• Pentoxifylline

Fatty Liver Treatment Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals
• Clinics

Fatty Liver Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Fatty Liver Treatment Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below are recent developments by fatty liver treatment producers in key regions: the USA, China, India, Japan, and Germany.

• United States: Advanced regulations have led to the approval of new drugs and therapies targeting non-alcoholic steatosis. Notably, the FDA approved a new class of drugs that have shown efficacy in reducing liver fat and inflammation. Additionally, research into personalized care approaches, including lifestyle interventions through digital health tools, is expanding.
• China: In China, there has been a strong push towards integrating traditional Chinese medicine with modern treatments. Recent clinical trials are investigating the effectiveness of herbal supplements combined with conventional therapies. The government is also increasing funding for research on fatty liver disease and promoting public awareness campaigns.
• Germany: In Germany, diagnostic technologies have advanced, improving the accuracy of fatty liver assessments through new imaging techniques. Combination therapies that address both liver fat and metabolic disorders are also being developed. These innovations are gradually being integrated into the national healthcare system.
• India: India has focused on making healthcare more affordable, particularly in rural areas. To lower costs, the country has introduced the production of generic formulations for existing drugs. Public health initiatives are also focused on educating the population about fatty liver disease.
• Japan: Japan has developed new guidelines for managing fatty liver disease that incorporate recent research findings into clinical practice. Furthermore, advanced therapeutics have been adopted, with several clinical trials launched to test new drug candidates and combination therapies.

Features of the Global Fatty Liver Treatment Market

Market Size Estimates: Fatty liver treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Fatty liver treatment market size by drug, end use, and region in terms of value ($B).

Regional Analysis: Fatty liver treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drugs, end uses, and regions for the fatty liver treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the fatty liver treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the fatty liver treatment market by drug (thiazolidinedione , vitamin e, metformin statins, polyunsaturated fatty acids, angiotensin receptor blockers, and pentoxifylline), end use (hospitals and clinics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Fatty Liver Treatment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Fatty Liver Treatment Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Fatty Liver Treatment Market by Drug
  • 3.3.1: Thiazolidinedione
  • 3.3.2: Vitamin E
  • 3.3.3: Metformin Statins
  • 3.3.4: Polyunsaturated fatty acids
  • 3.3.5: Angiotensin receptor blockers
  • 3.3.6: Pentoxifylline
• 3.4: Global Fatty Liver Treatment Market by End Use
  • 3.4.1: Hospitals
  • 3.4.2: Clinics

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Fatty Liver Treatment Market by Region
• 4.2: North American Fatty Liver Treatment Market
  • 4.2.1: North American Market by Drug: Thiazolidinedione , Vitamin E, Metformin Statins, Polyunsaturated fatty acids, Angiotensin receptor blockers, and Pentoxifylline
  • 4.2.2: North American Market by End Use: Hospitals and Clinics
• 4.3: European Fatty Liver Treatment Market
  • 4.3.1: European Market by Drug: Thiazolidinedione , Vitamin E, Metformin Statins, Polyunsaturated fatty acids, Angiotensin receptor blockers, and Pentoxifylline
  • 4.3.2: European Market by End Use: Hospitals and Clinics
• 4.4: APAC Fatty Liver Treatment Market
  • 4.4.1: APAC Market by Drug: Thiazolidinedione , Vitamin E, Metformin Statins, Polyunsaturated fatty acids, Angiotensin receptor blockers, and Pentoxifylline
  • 4.4.2: APAC Market by End Use: Hospitals and Clinics
• 4.5: ROW Fatty Liver Treatment Market
  • 4.5.1: ROW Market by Drug: Thiazolidinedione , Vitamin E, Metformin Statins, Polyunsaturated fatty acids, Angiotensin receptor blockers, and Pentoxifylline
  • 4.5.2: ROW Market by End Use: Hospitals and Clinics

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Fatty Liver Treatment Market by Drug
  • 6.1.2: Growth Opportunities for the Global Fatty Liver Treatment Market by End Use
  • 6.1.3: Growth Opportunities for the Global Fatty Liver Treatment Market by Region
• 6.2: Emerging Trends in the Global Fatty Liver Treatment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Fatty Liver Treatment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Fatty Liver Treatment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Cardax
• 7.2: Daewoong
• 7.3: Hoffmann-La Roche
• 7.4: Glenmark
• 7.5: GW Pharmaceuticals